Dako

Merck, Pfizer collaborate with Dako

Friday, September 25, 2015

As part of the global strategic alliance between Merck, based in Darmstadt, Germany, and Pfizer to jointly develop and commercialize avelumab, an investigational immune checkpoint inhibitor, the companies have announced a collaboration agreement with Dako, an Agilent Technologies company, for the development of a potential companion diagnostic test (CDx).

[Read More]

Dako, Ono Pharmaceutical to collaborate on diagnostic test Opdivo

Wednesday, February 18, 2015

Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, and Ono Pharmaceutical, headquartered in Osaka, Japan, have partnered to develop a potential diagnostic test specifically for use with Opdivo in the treatment of non-small cell lung cancer. This test is being investigated for its diagnostic utility to determine which patients are most likely to respond to Opdivo.

[Read More]